基于全米缩放和药理动力学建模方法,预测新组合蜂毒的首次人体剂量
Soon Uk Chae1, Jee Sun Min1, Seong Jun Jo1,2
1College of Pharmacy and Integrated Research Institute of Pharmaceutical Sciences, The Catholic University of Korea, Bucheon 14662, Korea.
Translational and clinical pharmacology
|April 10, 2025
概括
一种新的蜜蜂毒成分 (NCBV) 显示出对阿尔茨海默氏症的治疗有希望. 药物动力学建模预测了1.3毫克的安全首次人体剂量,用于NCBV,这是一种蜂毒酸酶A2 (bvPLA2) 强化的治疗方法.
科学领域:
- 药理学 药理学是指药理学的学科.
- 毒理学 毒理学 毒理学
- 神经科学是一个神经科学.
背景情况:
- 蜜蜂毒是一种用于神经和自身免疫疾病的传统疗法.
- 一种新的蜜蜂毒成分 (NCBV),富含蜜蜂毒酶A2 (bvPLA2),正在开发用于阿尔茨海默病治疗.
研究的目的:
- 使用机械性药理动力学 (PK) 方法预测NCBV的首次人体 (FIH) 剂量.
- 为即将进行的临床试验建立安全有效的起始剂量.
主要方法:
- 整合了三种物种的动物PK数据,以开发一个非线性混合效应的PK模型.
- 利用全度量测量 (简单,大脑重量,最大寿命潜力) 来预测人类PK参数.
- 根据有效的小鼠剂量和预测的人类PK参数,向后计算FIH剂量.
主要成果:
- 大脑重量全米缩放方法显示了预测人类PK参数的最高相关性 (R2 = 0.974).
- 预计70公斤人体的FIH初始剂量为5.5毫克 (简单),1.3毫克 (BrW) 和3.5毫克 (MLP).
- 建议皮下FIH剂量为1.3毫克NCBV,与没有观察到不良影响的0.1至3毫克水平范围保持一致.
结论:
- 机械PK建模方法成功预测了NCBV的安全FIH剂量.
- 推的1.3毫克皮下FIH剂量为启动针对阿尔茨海默病的NCBV临床试验提供了坚实的基础.
- NCBV显示出作为阿尔茨海默氏症治疗剂的潜力,需要进一步的临床研究.
相关概念视频
Pharmacokinetic Models: Comparison and Selection Criterion
26
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
26
Analysis of Population Pharmacokinetic Data
202
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
202
Pharmacokinetic Models: Overview
509
Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
509
Dose-Response Relationship: Overview
2.8K
Agonists can bind with and activate receptors, resulting in the formation of drug-receptor complexes. Once formed, these complexes catalyze many biochemical processes at the cellular level and subsequently induce a pharmacologic response. The degree of response is directly proportional to the fraction of activated receptors, which in turn, depends on the concentration of the drug at the receptor site as well as the sensitivity of the receptor. An increase in the administered dose contributes to...
2.8K
One-Compartment Open Model for Extravascular Administration: First-Order Absorption Model
173
The first-order absorption model for extravascular administration describes the rate at which a drug is absorbed and eliminated, following the principles of first-order kinetics. This model is vital as it provides a mathematical representation of drug behavior within the body. It also allows for the prediction and interpretation of drug absorption and elimination based on the rate of change in drug concentration over time. This model can be visualized as a plasma concentration-time profile...
173


